gammopathy, monoclonal

Showing 1 - 4 of 4

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Multiple Myeloma, Multiple Myeloma in Relapse, Tumors Trial (Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • +8 more
  • Belantamab Mafodotin-Blmf
  • +3 more
  • (no location specified)
Oct 13, 2022

Multiple Myeloma, Tumors, Tumor, Plasma Cell Trial (Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • +7 more
  • Belantamab Mafodotin-Blmf
  • +3 more
  • (no location specified)
Oct 11, 2022

Multiple Myeloma, Tumors, Tumors, Plasma Cell Trial (Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • +7 more
  • Belantamab Mafodotin-Blmf
  • +3 more
  • (no location specified)
Mar 4, 2022

IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy, IgM Monoclonal Gammopathy Trial in Atlanta (Rifaximin)

Recruiting
  • IgA Monoclonal Gammopathy
  • +8 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Oct 18, 2021